Paxman AB (PAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Paxman AB (PAX) has a cash flow conversion efficiency ratio of -0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.98 Million ≈ $-643.87K USD) by net assets (Skr427.76 Million ≈ $46.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Paxman AB stock valuation for the company's overall valuation and market capitalisation.
Paxman AB - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Paxman AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Paxman AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Paxman AB ranked by their cash flow conversion efficiency. Explore Paxman AB earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deutsche Konsum REIT AG
XETRA:DKG
|
-0.008x |
|
QuantumSi Inc
NASDAQ:QSI
|
-0.128x |
|
Wanhwa Enterprise Co
TW:2701
|
0.006x |
|
Hope Education Group Co. Ltd
F:HE1
|
0.049x |
|
Sam Young Chem
KO:003720
|
0.149x |
|
Feintool International Holding
SW:FTON
|
0.024x |
|
Bancroft Fund Limited
NYSE MKT:BCV
|
-0.198x |
|
Vente Unique.com
PA:ALVU
|
0.416x |
Annual Cash Flow Conversion Efficiency for Paxman AB (2017–2024)
The table below shows the annual cash flow conversion efficiency of Paxman AB from 2017 to 2024. View current stock price of Paxman AB for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr163.99 Million ≈ $17.65 Million |
Skr39.10 Million ≈ $4.21 Million |
0.238x | +87.04% |
| 2023-12-31 | Skr122.62 Million ≈ $13.20 Million |
Skr15.63 Million ≈ $1.68 Million |
0.127x | +442.03% |
| 2022-12-31 | Skr114.20 Million ≈ $12.29 Million |
Skr2.69 Million ≈ $289.06K |
0.024x | +171.39% |
| 2021-12-31 | Skr125.75 Million ≈ $13.53 Million |
Skr-4.14 Million ≈ $-445.85K |
-0.033x | +95.77% |
| 2020-12-31 | Skr10.89 Million ≈ $1.17 Million |
Skr-8.48 Million ≈ $-913.01K |
-0.779x | -768.59% |
| 2019-12-31 | Skr28.36 Million ≈ $3.05 Million |
Skr3.31 Million ≈ $355.67K |
0.117x | +639.81% |
| 2018-12-31 | Skr25.39 Million ≈ $2.73 Million |
Skr400.00K ≈ $43.05K |
0.016x | +107.24% |
| 2017-12-31 | Skr32.77 Million ≈ $3.53 Million |
Skr-7.13 Million ≈ $-767.62K |
-0.218x | -- |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of … Read more